A Review of PI3K Inhibitors in B-Cell Malignancies
Laura Cannon,(1) PharmD, MPH, Emmeline C. Academia,(2) PharmD, and Ashley E. Glode,(2) PharmD, BCOP
(1) The University of Texas at Austin College of Pharmacy and The University of Texas at Austin Dell Medical School LIVESTRONG Cancer Institutes, Austin, Texas; (2) UCHealth—University of Colorado Hospital and University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado
Authors’ disclosures of conflicts of interest are found at the end of this article.
Laura Cannon, PharmD, MPH, 2409 University Avenue, Stop A1910, Austin, TX 78712. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2019;10(7):717–725 |
© 2019 Harborside™
The phosphoinositide 3-kinase (PI3K) pathway plays a primary role in cellular proliferation and metabolism. Inhibition of the PI3K pathway is an emerging area of drug development and cancer research. Idelalisib, copanlisib, and duvelisib are currently the only U.S. Food & Drug Administration–approved PI3K inhibitors available for use in hematologic malignancies. These PI3K inhibitors differ in their recommended indications, selectivity of PI3K isoforms, dosing, and potential toxicities. Several ongoing studies are aiming to expand the use of such drugs and identify unique combination regimens. This article discusses the current data supporting their place in therapy for B-cell malignancies, management of adverse events, and the clinical implications for advanced practitioners for the commercially available PI3K inhibitors.
For access to the full length article, please sign in